Solabegron
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for Solabegron, covering 2008-10-16 to 2020-03-02. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) [Phase 2]